Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Restructuring Reserve Liability by Year
Restructuring Reserve Liability — Total ending balance ($M) ($M)
Pfizer Restructuring Reserve Liability: $1,910M in FY2025, down 9.9% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Tracks Pfizer's multi-year Cost Realignment Program (~$4.9B cumulative costs through Q2 2026) and Manufacturing Optimization Program (~$1.1B cumulative costs through Q2 2026).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Restructuring Reserve Liability — Total ending balance ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,910 | -9.9% | Form 10-Q (filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 2,120 | +6.6% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 1,988 | +65.1% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1,204 | +12.4% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 1,071 | +34.2% | Form 10-K (filed 2024-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 798 | -2.2% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 816 | -29.7% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 1,161 | +5.1% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 1,105 | -30.2% | Form 10-K (filed 2020-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 1,583 | +36.8% | Form 10-K (filed 2019-02-28) ↗ |
| FY2015 | Dec 31, 2015 | 1,157 | – | Form 10-K (filed 2018-02-22) ↗ |
Breakdown
What makes up restructuring Reserve Liability
- Restructuring reserve — Current liability ($M)1,400 · FY2025
- Restructuring reserve — Noncurrent liability ($M)466 · FY2025
- Restructuring reserve — Employee termination / severance costs ($M)1,783 · FY2025
- Restructuring reserve — Exit & other restructuring activities ($M)127 · FY2025
- Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M)4,200 · FY2025
- Cost Realignment Program — Cumulative costs attributable to Biopharma ($M)3,200 · FY2025
- Cost Realignment Program — Total expected program one-time costs ($M)–
- Manufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M)1,100 · FY2025
- Manufacturing Optimization Program — Total expected Phase 1 costs ($M)1,400 · FY2025
- Restructuring charges recognized in period — Total ($M)1,092 · FY2025
- Restructuring charges — Employee termination costs ($M)684 · FY2025
- Restructuring-related asset impairments ($M)349 · FY2025
- Restructuring charges — Exit & other costs ($M)59 · FY2025
- Restructuring reserve utilization / cash payments — Total ($M)1,302 · FY2025
- Restructuring reserve utilization — Severance payments ($M)947 · FY2025
- Acquisition integration & implementation costs ($M)1,965 · FY2025
Cite this data
StockData. (2026). Pfizer Restructuring Reserve Liability ($M), annual FY2015–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-res-tot
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.